BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 30115224)

  • 1. Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Preserved Systolic Function.
    Mentias A; Raeisi-Giglou P; Smedira NG; Feng K; Sato K; Wazni O; Kanj M; Flamm SD; Thamilarasan M; Popovic ZB; Lever HM; Desai MY
    J Am Coll Cardiol; 2018 Aug; 72(8):857-870. PubMed ID: 30115224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incremental Prognostic Utility of Left Ventricular Global Longitudinal Strain in Hypertrophic Obstructive Cardiomyopathy Patients and Preserved Left Ventricular Ejection Fraction.
    Tower-Rader A; Betancor J; Popovic ZB; Sato K; Thamilarasan M; Smedira NG; Lever HM; Desai MY
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29054839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy.
    Chan RH; Maron BJ; Olivotto I; Pencina MJ; Assenza GE; Haas T; Lesser JR; Gruner C; Crean AM; Rakowski H; Udelson JE; Rowin E; Lombardi M; Cecchi F; Tomberli B; Spirito P; Formisano F; Biagini E; Rapezzi C; De Cecco CN; Autore C; Cook EF; Hong SN; Gibson CM; Manning WJ; Appelbaum E; Maron MS
    Circulation; 2014 Aug; 130(6):484-95. PubMed ID: 25092278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy.
    Klopotowski M; Kukula K; Malek LA; Spiewak M; Polanska-Skrzypczyk M; Jamiolkowski J; Dabrowski M; Baranowski R; Klisiewicz A; Kusmierczyk M; Jasinska A; Jarmus E; Kruk M; Ruzyllo W; Witkowski A; Chojnowska L
    J Cardiol; 2016 Jul; 68(1):49-56. PubMed ID: 26363820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between myocardial fibrosis detected by cardiac magnetic resonance and Tp-e interval, 5-year sudden cardiac death risk score in hypertrophic cardiomyopathy patients.
    Riza Demir A; Celik Ö; Sevinç S; Uygur B; Kahraman S; Yilmaz E; Cemek M; Onal Y; Erturk M
    Ann Noninvasive Electrocardiol; 2019 Sep; 24(5):e12672. PubMed ID: 31152489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of late gadolinium enhancement quantification in cardiac magnetic resonance imaging of hypertrophic cardiomyopathy with systolic dysfunction.
    Funada A; Kanzaki H; Noguchi T; Morita Y; Sugano Y; Ohara T; Hasegawa T; Hashimura H; Ishibashi-Ueda H; Kitakaze M; Yasuda S; Ogawa H; Anzai T
    Heart Vessels; 2016 May; 31(5):758-70. PubMed ID: 25820658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between the quantitative extent of late gadolinium enhancement and burden of nonsustained ventricular tachycardia in hypertrophic cardiomyopathy: A delayed contrast-enhanced magnetic resonance study.
    Weissler-Snir A; Hindieh W; Spears DA; Adler A; Rakowski H; Chan RH
    J Cardiovasc Electrophysiol; 2019 May; 30(5):651-657. PubMed ID: 30680853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Late gadolinium enhancement is common in patients with hypertrophic cardiomyopathy and no clinical risk factors for sudden cardiac death: A single center experience.
    Lyons KS; Dixon LJ; Johnston N; Noad R; Hamilton A; McKeag N; Horan P
    Cardiol J; 2014; 21(1):29-32. PubMed ID: 23990187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death.
    Freitas P; Ferreira AM; Arteaga-Fernández E; de Oliveira Antunes M; Mesquita J; Abecasis J; Marques H; Saraiva C; Matos DN; Rodrigues R; Cardim N; Mady C; Rochitte CE
    J Cardiovasc Magn Reson; 2019 Aug; 21(1):50. PubMed ID: 31412875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Midwall Late Gadolinium Enhancement and Sudden Cardiac Death in Patients With Dilated Cardiomyopathy and Mild and Moderate Left Ventricular Systolic Dysfunction.
    Halliday BP; Gulati A; Ali A; Guha K; Newsome S; Arzanauskaite M; Vassiliou VS; Lota A; Izgi C; Tayal U; Khalique Z; Stirrat C; Auger D; Pareek N; Ismail TF; Rosen SD; Vazir A; Alpendurada F; Gregson J; Frenneaux MP; Cowie MR; Cleland JGF; Cook SA; Pennell DJ; Prasad SK
    Circulation; 2017 May; 135(22):2106-2115. PubMed ID: 28351901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term risk of sudden cardiac death in hypertrophic cardiomyopathy: a cardiac magnetic resonance outcome study.
    Greulich S; Seitz A; Herter D; Günther F; Probst S; Bekeredjian R; Gawaz M; Sechtem U; Mahrholdt H
    Eur Heart J Cardiovasc Imaging; 2021 Jun; 22(7):732-741. PubMed ID: 33458753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of basal-septal fibrosis with LV outflow tract obstruction in hypertrophic cardiomyopathy: insights from cardiac magnetic resonance analysis.
    Nakamura T; Iwanaga Y; Yasuda M; Kawamura T; Miyaji Y; Morooka H; Miyazaki S
    Int J Cardiovasc Imaging; 2016 Apr; 32(4):613-20. PubMed ID: 26589516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Benefit of Cardiac Magnetic Resonance Over Transthoracic Echocardiography for the Assessment of Ischemic and Nonischemic Dilated Cardiomyopathy Patients Referred for the Evaluation of Primary Prevention Implantable Cardioverter-Defibrillator Therapy.
    Pontone G; Guaricci AI; Andreini D; Solbiati A; Guglielmo M; Mushtaq S; Baggiano A; Beltrama V; Fusini L; Rota C; Segurini C; Conte E; Gripari P; Dello Russo A; Moltrasio M; Tundo F; Lombardi F; Muscogiuri G; Lorenzoni V; Tondo C; Agostoni P; Bartorelli AL; Pepi M
    Circ Cardiovasc Imaging; 2016 Oct; 9(10):. PubMed ID: 27729359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ESC sudden-death risk model in hypertrophic cardiomyopathy: Incremental value of quantitative contrast-enhanced CMR in intermediate-risk patients.
    Hinojar R; Zamorano JL; Gonzalez Gómez A; Plaza Martin M; Esteban A; Rincón LM; Portugal JC; Jimenez Nácher JJ; Fernández-Golfín C
    Clin Cardiol; 2017 Oct; 40(10):853-860. PubMed ID: 28614597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Role of Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Low-to-Intermediate Sudden Cardiac Death Risk Score.
    Todiere G; Nugara C; Gentile G; Negri F; Bianco F; Falletta C; Novo G; Di Bella G; De Caterina R; Zachara E; Re F; Clemenza F; Sinagra G; Emdin M; Aquaro GD
    Am J Cardiol; 2019 Oct; 124(8):1286-1292. PubMed ID: 31447011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Predicting value of 2014 European guidelines risk prediction model for sudden cardiac death (HCM Risk-SCD) in Chinese patients with hypertrophic cardiomyopathy].
    Li WX; Liu LW; Wang J; Zuo L; Yang F; Kang N; Lei CH
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Dec; 45(12):1033-1038. PubMed ID: 29325362
    [No Abstract]   [Full Text] [Related]  

  • 17. Prognostic significance of late gadolinium enhancement on cardiac magnetic resonance in patients with hypertrophic cardiomyopathy.
    He D; Ye M; Zhang L; Jiang B
    Heart Lung; 2018; 47(2):122-126. PubMed ID: 29174363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The value of cardiac MRI in the risk stratification in patients with hypertrophic cardiomyopathy].
    Wang JX; Yang SJ; Ma X; Yu SQ; Dong ZX; Xiang XR; Wei ZX; Cui C; Yang K; Chen XY; Lu MJ; Zhao SH
    Zhonghua Xin Xue Guan Bing Za Zhi; 2023 Jun; 51(6):619-625. PubMed ID: 37312480
    [No Abstract]   [Full Text] [Related]  

  • 19. Entropy of left ventricular late gadolinium enhancement and its prognostic value in hypertrophic cardiomyopathy a new CMR assessment method.
    Zhao X; Jin F; Wang J; Zhao X; Wang L; Wei H
    Int J Cardiol; 2023 Feb; 373():134-141. PubMed ID: 36395920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and Progression of Late Gadolinium Enhancement in Children and Adolescents With Hypertrophic Cardiomyopathy.
    Axelsson Raja A; Farhad H; Valente AM; Couce JP; Jefferies JL; Bundgaard H; Zahka K; Lever H; Murphy AM; Ashley E; Day SM; Sherrid MV; Shi L; Bluemke DA; Canter CE; Colan SD; Ho CY
    Circulation; 2018 Aug; 138(8):782-792. PubMed ID: 29622585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.